Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC

Research Article

This study focused on comparing the efficacy of uniportal three-dimensional (3D) video-assisted thoracic surgery (VATS) lobectomy and traditional two-dimensional (2D) VATS lobectomy in patients with non-small cell lung cancer (NSCLC).
A retrospective analysis was performed on 84 NSCLC patients who underwent VATS lobectomy. Based on the type of thoracoscope used during surgery, patients were assigned to either the 3D group (n = 42), which received uniportal 3D VATS lobectomy, or the 2D group (n = 42), which underwent traditional 2D VATS lobectomy.

Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report

Case Report

The distinction between a metastatic recurrence and the onset of a second primary malignancy can be diagnostically challenging. Precision medicine can offer valuable support in this context.
A 34-year-old woman was diagnosed in 2012 with hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in the left breast, with homolateral axillary node involvement but no distant metastases.

A literature review of radio-genomics in breast cancer: Lessons and insights for low and middle-income countries

Review Article

To improve precision medicine in breast cancer (BC) decision-making, radio-genomics is an emerging branch of artificial intelligence (AI) that links cancer characteristics assessed radiologically with the histopathology and genomic properties of the tumour. By employing MRIs, mammograms, and ultrasounds to uncover distinctive radiomics traits that potentially predict genomic abnormalities, this review attempts to find literature that links AI-based models with the genetic mutations discovered in BC patients.

Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients

Research Article

Recent advancements in identifying druggable molecular drivers in lung adenocarcinoma (LUAD), have transformed treatment paradigms. In recent years, Next Generation Sequencing (NGS) has gained momentum as an essential tool for in-depth simultaneous analysis of multiple genes, thereby streamlining the diagnostic process in LUAD. Despite this, the implementation of NGS testing in both the US and Europe remains suboptimal.

Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization

Research Article

Anti-HER2 drugs are becoming an important therapeutic option for various solid tumors, increasing the need for HER2 status testing. Comprehensive genomic profiling (CGP) panels, including FoundationOne®CDx, are commonly used to assess ERBB2 (encoding for HER2) copy number alterations. We aimed to evaluate the analytical validity of FoundationOne®CDx assay, by comparing ERBB2 copy number data with traditional HER2 status by immunohistochemistry (IHC)/in situ hybridization (ISH) assays in a heterogeneous cohort of solid tumor samples.